Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 7/20 | 0.39 |
| ▸ | ESR1 | P03372 | 6/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | LPL | P06858 | 4/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29978910 | 1.00 | ESR2 (0.39) | ESR2ESR1CYP3A4CHRM1ALOX15 | |
| SCHEMBL18039553 | 0.85 | ACHE (0.37) | ESR2ESR1CYP3A4LPLLIPG | |
| SCHEMBL5477046 | 0.83 | LPL (0.35) | LPLLIPGF11CA12CA9 | |
| SCHEMBL7162437 | 0.81 | LPL (0.38) | CYP3A4ALOX15LPLLIPGLMNA | |
| SCHEMBL29424563 | 0.81 | LPL (0.38) | CYP3A4ALOX15LPLLIPGLMNA | |
| SCHEMBL14696435 | 0.81 | LIPG (0.45) | CYP3A4LPLLIPGCA12ALDH1A1 | |
| SCHEMBL257904 | 0.80 | LPL (0.40) | ESR2ESR1LPLLIPGF11 | |
| SCHEMBL29748917 | 0.80 | LPL (0.40) | ESR2ESR1LPLLIPGF11 | |
| SCHEMBL10269959 | 0.80 | HSD17B10 (0.42) | ESR2ESR1LPLLIPGCA12 | |
| SCHEMBL29352199 | 0.80 | HSD17B10 (0.42) | ESR2ESR1LPLLIPGCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492174-B2 | Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP4) agonists for the treatment of gastrointestinal and pulmonary diseases | NXERA PHARMA UK LIMITED (GB) | 2025-12-09 | — | — | US | disclosed |
| US-20250179036-A1 | MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | NXERA PHARMA UK LIMITED (GB) | 2025-06-05 | — | — | US | disclosed |
| US-20250115613-A1 | DIARYL COMPOUND AS TUBULIN/SRC DUAL TARGET INHIBITOR | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-04-10 | — | — | US | disclosed |
| EP-4464700-A1 | DIARYL COMPOUND AS TUBULIN/SRC DUAL TARGET INHIBITOR | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2024-11-20 | — | — | EP | disclosed |
| CN-117624139-A | Diaryl compound, preparation method and application thereof | 武汉人福创新药物研发中心有限公司 | 2024-03-01 | — | — | CN | disclosed |
| WO-2024041628-A1 | DIARYL COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2024-02-29 | — | — | WO | disclosed |
| WO-2024028604-A1 | MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-02-08 | — | — | WO | disclosed |
| WO-2023134752-A1 | DIARYL COMPOUND AS TUBULIN/SRC DUAL TARGET INHIBITOR | 武汉人福创新药物研发中心有限公司 | 2023-07-20 | — | — | WO | disclosed |
| CN-116444427-A | Diaryl compounds for tubulin-SRC double-target inhibitor | 武汉人福创新药物研发中心有限公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-116157388-A | Carbocyclic amide derivative and application thereof in medicine | 四川海思科制药有限公司 | 2023-05-23 | — | — | CN | disclosed |
| WO-2008051942-A2 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008051942-A2 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-02 | — | — | WO | disclosed |
| US-20080096921-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096921-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096921-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-24 | — | — | US | disclosed |
| WO-2007140183-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007140174-A2 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007096072-A2 | NEW PYRIDIN-3-AMINE DERIVATIVES | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007096072-A2 | NEW PYRIDIN-3-AMINE DERIVATIVES | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007092751-A2 | COMPOUNDS AND METHODS FOR MODULATING FX-RECEPTORS | ELI LILLY AND COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115613-A1 | DIARYL COMPOUND AS TUBULIN/SRC DUAL TARGET INHIBITOR | SRC, DSTYK, TUBB1 | ESR2 4377/4885ESR1 3726/4885CYP3A4 1996/4885 |
| US-12492174-B2 | Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP4) agonists for the treatment of gastrointestinal and pulmonary diseases | PTGER4, PTGER1, PTGER2 | ESR2 128/4885ESR1 608/4885CYP3A4 197/4885 |
| US-20080096921-A1 | FARNESOID X RECEPTOR AGONISTS | NR1H4, NR1H3, NR1H2 | ESR2 246/4885ESR1 362/4885CYP3A4 110/4885 |
| US-20250179036-A1 | MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | PTGER4, PTGER1, PTGER2 | ESR2 128/4885ESR1 608/4885CYP3A4 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.